Navigation Links
MJFF Funds Two Investigations of Placebo Effect in Parkinson's Disease
Date:12/29/2009

NEW YORK, Dec. 29 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research announced funding for two projects investigating the placebo effect in Parkinson's disease.

Placebo treatments are harmless, inactive substances administered to some of the patients in a clinical trial to provide a baseline comparison for measuring the effects of active treatment given to other patients in the trial. The placebo effect -- in which patients who receive an inert substance nonetheless experience some or all benefits of active treatment -- is a topic of growing interest to Parkinson's researchers. The placebo effect has increasingly complicated the interpretation of outcomes from PD clinical trials, creating a significant hurdle to the development of new treatments. And it may have a greater impact in clinical trials for Parkinson's than other diseases, because it involves the dopamine system, which degenerates in PD.

As part of a clinical trial in dyskinesia announced by the Foundation earlier this month, a pilot study will seek to initially validate surveys that can predict how placebo response is impacted from person to person by disease- and treatment-related variables, as well as by individual personality characteristics of patients and investigators involved in clinical research. The pilot will assess the potential validity of the placebo surveys for other future clinical trials, as well as provide ancillary information on various dyskinesia rating scales' susceptibility to placebo effects. Researchers Mark Stacy, MD, of Duke University and Glenn T. Stebbins, PhD, of Rush University Medical Center will compile and develop surveys to be administered to patients and investigators at the outset of the study. These surveys will gather data on personal traits including optimism, social conformity and expectations of outcome. At the close of the trial, the survey results will be tracked with study outcomes to determine the impact of optimism and expectation of positive outcome on the effectiveness of different dyskinesia rating scales.

A Columbia University team led by Tor Wager, PhD, and Daphna Shohamy, PhD, will use functional magnetic resonance imaging (fMRI) to look at brain activity in Parkinson's patients as they execute specific motor and learning tasks, comparing how brain activity changes when the patients are given levodopa (the gold-standard treatment for Parkinson's disease) versus placebo. While previous imaging studies have demonstrated that placebo treatments can increase dopamine levels in patients' brains, there is little experimental evidence that these increased dopamine levels are tied to functional improvement on the Unified Parkinson's Disease Rating Scale (UPDRS), the tool used by clinicians to measure effects of experimental treatments. Drs. Wager and Sohamy will evaluate the potential of fMRI to provide such evidence. The goal is to more fully establish biological markers of placebo effects in PD and determine whether placebo effects lead to measurable functional improvement for patients.

The funded projects announced today were catalyzed in part by The Michael J. Fox Foundation's Placebo Response workshop held in March 2009. The workshop, co-funded by The Davis Phinney Foundation, convened leading experts to discuss and prioritize strategies for helping the field gain a greater understanding of placebo effects in PD in order to improve the design and testing of future therapeutics.

About The Michael J. Fox Foundation

The Michael J. Fox Foundation is dedicated to ensuring the development of better treatments, and ultimately a cure, for Parkinson's disease through an aggressively funded research agenda. MJFF has funded nearly $170 million in research to date.

SOURCE Michael J. Fox Foundation


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Poland Spring Contributes Funds for Kingfield Helipad Construction Project to Help Save Lives
2. Exposing the Double Standard of the Forgotten Cancer: Biggest Cancer Killer for Women and Men, Lung Cancer, Receives Least Research Funds
3. Julian Lennon and James Scott Cook Release New Charity Single LUCY to Raise Awareness and Funds for Lupus Research
4. Comcast and Stand Up To Cancer Launch First-Ever Video-on-Demand Effort to Broaden Awareness and Raise Funds for Cancer Research
5. Esperanza Health Center Receives $6.5 Million in Stimulus Funds
6. Injury Funds Now To the Rescue with New Lawsuit Funding Service
7. Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists
8. Drummond Group Awarded DOE Funds for Texas Wind Integration Project
9. Salon Leau to Host Cuts for a Cause to Raise Funds and Spread the Word About Childhood Terminal Illnesses
10. Raising Millions for Team Challenge through Rock ‘n' Roll Las Vegas Half Marathon Program Brings Hundreds From Across the Country to Raise Funds for Crohn's & Colitis
11. New Reid Bill Funds Abortion: Excludes Bipartisan Stupak-Pitts Amendment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, and ... in the eye of the beholder, according to experts who offered insights and commentary ... of Managed Care. For the full issue, click here . , For the ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology: